Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 176.50 GBp
Change Today 0.00 / 0.00%
Volume 0.0
NSCI On Other Exchanges
Symbol
Exchange
London
Frankfurt
As of 6:00 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

netscientific plc (NSCI) Snapshot

Open
176.50 GBp
Previous Close
176.50 GBp
Day High
176.50 GBp
Day Low
176.50 GBp
52 Week High
05/29/15 - 210.00 GBp
52 Week Low
04/21/15 - 112.50 GBp
Market Cap
63.4M
Average Volume 10 Days
9.2K
EPS TTM
-0.18 GBp
Shares Outstanding
35.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NETSCIENTIFIC PLC (NSCI)

Related News

No related news articles were found.

netscientific plc (NSCI) Related Businessweek News

No Related Businessweek News Found

netscientific plc (NSCI) Details

NetScientific plc is a venture capital firm specializing in early and mid stage investments. The firm focuses to invest in transformative biomedical and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. Within digital health it focuses on data analytics, wearable technologies, and devices. The firm seeks to invest in companies based in Britain and the United States. It typically invests up to £0.25 million ($0.49 million), but may consider larger amounts. It prefers to hold a controlling interest in all principal subsidiaries. NetScientific plc is based in London, United Kingdom.

23 Employees
Last Reported Date: 05/18/15

netscientific plc (NSCI) Top Compensated Officers

Chief Financial Officer and Executive Directo...
Total Annual Compensation: 135.0K GBP
Chief Operating Officer, Head of US Investmen...
Total Annual Compensation: 150.0K GBP
Chief Technology Officer, Head of European In...
Total Annual Compensation: 100.0K GBP
Director of Commercial and Legal and Executiv...
Total Annual Compensation: 110.0K GBP
Compensation as of Fiscal Year 2014.

netscientific plc (NSCI) Key Developments

NetScientific plc, Annual General Meeting, Jun 22, 2015

NetScientific plc, Annual General Meeting, Jun 22, 2015., at 11:00 GMT Standard Time. Location: Regus Office. Agenda: To receive and adopt the company’s Annual Report and accounts for the financial year ended 31 December 2014; to reappoint BDO LLP as auditors of the company; to authorize the directors of the company to determine the remuneration of the auditors; to consider the reappointment of directors of the company; to give approval to increase the aggregate number of shares over which options may be granted under the NetScientifc Share Option Scheme; to allot shares in the company; and to allot equity securities for cash.

NetScientific plc Announces Management Changes

NetScientific plc announced the appointment of Dr. François R. Martelet as Chief Executive Officer and Board Director. Dr. Martelet will join the Group on 8 June 2015. Sir. Richard Sykes, who has been Executive Chairman prior to this appointment, will revert to his position as Non-Executive Chairman. Most recently, Dr. Martelet has served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies.

NetScientific plc Forms New Digital Health Company in Partnership with iMPak Health, LLC

NetScientific plc has formed a new digital health sales and marketing subsidiary company, Triventis Health LLC (Triventis) in partnership with iMPak Health, LLC (iMPak), a wholly owned subsidiary of Meridian Health Hospital Group, New Jersey, USA. Triventis will provide smart digital healthcare solutions, enabling better patient data collection, connectivity and software to give healthcare providers actionable clinical data. The new company will have its own sales force to sell and market the integrated solutions provided by a combination of Wanda Health's (a NetScientific subsidiary) cloud-based information analytics and iMPak's healthcare expertise and innovative easy-to-use medical devices, to intelligently monitor and manage patients. This unique healthcare management product has undergone trial and will be adopted by the Meridian Hospital Group - which consists of six hospitals, 100 facility locations and generates $1.6 billion in revenue. The product will then roll out across the USA to other healthcare providers. The initial product provides continuous monitoring and assessment of patients with Congestive Heart Failure (CHF). Triventis will distribute other Wanda Health applications, notably for patients with co-morbidities and iMPak's next generation medication management to help improve compliance with prescription schedules.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSCI:LN 176.50 GBp 0.00

NSCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NSCI.
View Industry Companies
 

Industry Analysis

NSCI

Industry Average

Valuation NSCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NETSCIENTIFIC PLC, please visit www.netscientific.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.